All News
Filter News
Found 180 articles
-
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
11/28/2022
Exscientia plc (Nasdaq: EXAI) today announced clinical trial application (CTA) approval of IGNITE-AI, enabling site activation in its first European country.
-
Exscientia Business and Financial Update for the Third Quarter 2022
11/15/2022
Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the third quarter 2022, are summarised below. Exscientia will host a conference call today, November 15, at 1:30 p.m. GMT / 8:30 a.m. ET.
-
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
11/14/2022
Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.
-
Sanofi entered into a partnership with Insilico Medicine to develop drugs for up to six targets. The deal is worth a potential $1.2 billion.
-
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
11/8/2022
Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2022, on Tuesday, November 15, 2022, before the open of U.S. markets.
-
Rallybio Reports Third Quarter 2022 Financial Results
11/7/2022
Rallybio Corporation, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, reported financial results for the third quarter ended September 30, 2022 and provided an update on recent program and corporate developments.
-
Exscientia Expands Biologics Design Capability with Automated Laboratory
11/3/2022
Exscientia plc (Nasdaq: EXAI) today announced the expansion of its platform to include the design of biologics, such as human antibodies.
-
Exscientia to Present at Upcoming Investor Conferences in November
11/1/2022
Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November.
-
Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium
10/26/2022
Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium.
-
Immuno-Oncology Clinical Trials Market Size to Surpass USD 18.1 Bn by 2030
10/17/2022
According to the global Immuno-Oncology Clinical Trials market size is expected to surpass around USD 18.1 billion by 2030 from valued at USD 6.3 billion in 2021 and growing at a CAGR of 14.6% from 2022 to 2030.
-
Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes
9/20/2022
Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Blood Cancer Discovery, a journal of the American Association for Cancer Research, titled “Deep Morphology Learning Enhances Precision Medicine by Image-Based Ex Vivo Drug Testing” from the laboratory of Prof. Berend Snijder.
-
Homology Medicines and MiMedx both posted new CEOs. Other C-suite positions, including CFOs and CMOs were also filled this week.
-
Exscientia to Present at Upcoming Investor Conferences in September 2022
9/7/2022
Exscientia announced that Company management will participate in the following investor conferences in September.
-
TandemAI Announces Appointment of Steve Swann, Ph.D., as Chief Scientific Officer
8/25/2022
TandemAI today announced the appointment of Steve Swann, Ph.D., to the newly created position of Chief Scientific Officer.
-
Exscientia Business Update for Second Quarter and First Half 2022
8/17/2022
Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below.
-
Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate Updates
8/11/2022
Other non-operating result of € (89.8) m (H1 2021: € 106.1 m) explained by the non-cash fair value adjustments of the equity investment in publicly listed Exscientia plc.
-
Exscientia to Report Second Quarter 2022 Financial Results on August 17, 2022
8/10/2022
Exscientia will report financial results for the second quarter ended June 30, 2022, on Wednesday, August 17, 2022 after U.S. market close.
-
Artificial Intelligence In Drug Discovery Market Size to Surpass US$ 9.7 BN By 2030
8/10/2022
Latest Study on “Artificial Intelligence In Drug Discovery Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.
-
AI in Drug Discovery Market: Increase in cross-industry alliances and collaborations to Drive the Market
8/3/2022
Wilmington, Delaware, United States, Transparency Market Research Inc.: Artificial intelligence has caught the attention and minds of medical technology practitioners in the past few years, as several companies and major research laboratories have worked to perfect these technologies for clinical use.
-
AI in Drug Discovery Market Size, Share, Trends, Growth | Report 2022 to 2030
7/13/2022
Quick drug identification for COVID-19 could serve as a boon, as many countries struggle to contain the deadly virus.